Elizabeth Hardaker

1.8k total citations
23 papers, 844 citations indexed

About

Elizabeth Hardaker is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Elizabeth Hardaker has authored 23 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 8 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Elizabeth Hardaker's work include Asthma and respiratory diseases (5 papers), Immune Response and Inflammation (3 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers). Elizabeth Hardaker is often cited by papers focused on Asthma and respiratory diseases (5 papers), Immune Response and Inflammation (3 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers). Elizabeth Hardaker collaborates with scholars based in United Kingdom, United States and Switzerland. Elizabeth Hardaker's co-authors include Maria G. Belvisi, Mark A. Birrell, Kerryn McCluskie, Sissie Wong, Matthew C. Catley, Saleem Haj‐Yahia, Robert Newton, Simon Lea, Josiah Dungwa and Dave Singh and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Elizabeth Hardaker

23 papers receiving 819 citations

Peers

Countries citing papers authored by Elizabeth Hardaker

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Hardaker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Hardaker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Hardaker more than expected).

Fields of papers citing papers by Elizabeth Hardaker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Hardaker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Hardaker. The network helps show where Elizabeth Hardaker may publish in the future.

Co-authorship network of co-authors of Elizabeth Hardaker

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Hardaker. A scholar is included among the top collaborators of Elizabeth Hardaker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Hardaker. Elizabeth Hardaker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities 2025 ·Journal of Experimental & Clinical Cancer Research ·Lais C. G. F. Palhares, Melanie Grandits, (unknown), Jitesh Chauhan, (unknown), Gilbert O. Fruhwirth, Sophia Tsoka, James R. Birtley, Leanne Partington, T. Wilson, Elizabeth Hardaker, Sophia N. Karagiannis, Heather J. Bax, Kevin Fitzgerald	1
2	Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality 2025 ·mAbs ·Melanie Grandits, Lais C. G. F. Palhares, (unknown), John W. Devlin, Oliver E. Amin, James R. Birtley, Leanne Partington, T. Wilson, Elizabeth Hardaker, Sophia N. Karagiannis, Heather J. Bax, Kevin Fitzgerald	1
3	Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors 2025 ·Journal for ImmunoTherapy of Cancer ·Melanie Grandits, Lais C. G. F. Palhares, Gabriel Osborn, Jitesh Chauhan, (unknown), (unknown), (unknown), (unknown), Alicia M. Chenoweth, (unknown), Jacobo López‐Abente, Kristina M. Ilieva, James R. Birtley, Sophia Tsoka, Elizabeth Hardaker, Kevin Fitzgerald, Sophia N. Karagiannis, Heather J. Bax	3
4	Development of autotaxin inhibitors: A series of tetrazole cinnamides 2020 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Mark R. Dowling, David T. Beattie, (unknown), Michael Faller, Mark Freeman, Elizabeth Hardaker, (unknown), René Hemmig, (unknown), (unknown), David D. Pascoe, (unknown), Binesh Shrestha, (unknown), (unknown)	3
5	A multi-batch design to deliver robust estimates of efficacy and reduce animal use – a syngeneic tumour case study 2020 ·Scientific Reports ·Natasha A. Karp, Zena Wilson, (unknown), Lorraine Mooney, Stanley E. Lazic, (unknown), Elizabeth Hardaker	22
6	Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery 2019 ·Journal for ImmunoTherapy of Cancer ·Molly A. Taylor, Adina Hughes, Josephine Walton, Anna Coenen-Stass, Łukasz Magiera, Lorraine Mooney, (unknown), Anna D. Staniszewska, Linda C. Sandin, Simon T. Barry, Amanda Watkins, Larissa S. Carnevalli, Elizabeth Hardaker	70
7	Development of autotaxin inhibitors: A series of zinc binding triazoles 2018 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Mark R. Dowling, Cara E. Brocklehurst, (unknown), (unknown), Michael Faller, Mark Freeman, (unknown), (unknown), (unknown), Elizabeth Hardaker, (unknown), (unknown), (unknown), David Pearce, (unknown), (unknown), (unknown)	9
8	PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity 2018 ·Journal for ImmunoTherapy of Cancer ·Larissa S. Carnevalli, Charles Sinclair, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna Coenen-Stass, Lorraine Mooney, Adina Hughes, (unknown), Anna D. Staniszewska, Claire Crafter, Ben S. Sidders, Elizabeth Hardaker, Kevin Hudson, Simon T. Barry	71
9	Characterisation of lung macrophage subpopulations in COPD patients and controls 2017 ·Scientific Reports ·(unknown), Simon Lea, Elizabeth Hardaker, Josiah Dungwa, Arjun Ravi, Dave Singh	92
10	Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin 2011 ·Journal of Cystic Fibrosis ·Ellena Growcott, Alan Coulthard, Richard T. Amison, Elizabeth Hardaker, (unknown), (unknown), Peter Lloyd Jones, Armelle Grevot, Chris Poll, Colin Osborne, (unknown)	18
11	Liver X Receptor Agonists Increase Airway Reactivity in a Model of Asthma via Increasing Airway Smooth Muscle Growth 2008 ·The Journal of Immunology ·Mark A. Birrell, Jorge De Alba, Matthew C. Catley, Elizabeth Hardaker, Sissie Wong, Michael P. Collins, Deborah Clarke, Stuart Farrow, Timothy M. Willson, Jon L. Collins, Maria G. Belvisi	23
12	Estrogen Receptor β: Expression Profile and Possible Anti-Inflammatory Role in Disease 2008 ·Journal of Pharmacology and Experimental Therapeutics ·Matthew C. Catley, Mark A. Birrell, Elizabeth Hardaker, Jorge De Alba, Stuart Farrow, Saleem Haj‐Yahia, Maria G. Belvisi	25
13	Novel Role for the Liver X Nuclear Receptor in the Suppression of Lung Inflammatory Responses 2007 ·Journal of Biological Chemistry ·Mark A. Birrell, Matthew C. Catley, Elizabeth Hardaker, Sissie Wong, Timothy M. Willson, Kerryn McCluskie, Thomas B. Leonard, Stuart Farrow, Jon L. Collins, Saleem Haj‐Yahia, Maria G. Belvisi	53
14	IκB Kinase-2-Independent and -Dependent Inflammation in Airway Disease Models: Relevance of IKK-2 Inhibition to the Clinic 2006 ·Molecular Pharmacology ·Mark A. Birrell, Sissie Wong, Elizabeth Hardaker, Matthew C. Catley, Kerryn McCluskie, Michael P. Collins, Saleem Haj‐Yahia, Maria G. Belvisi	41
15	Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model 2006 ·European Respiratory Journal ·Mark A. Birrell, Kerryn McCluskie, Elizabeth Hardaker, Richard Knowles, Maria G. Belvisi	34
16	Second-Generation Inhibitors Demonstrate the Involvement of p38 Mitogen-Activated Protein Kinase in Post-Transcriptional Modulation of Inflammatory Mediator Production in Human and Rodent Airways 2006 ·Journal of Pharmacology and Experimental Therapeutics ·Mark A. Birrell, Sissie Wong, Kerryn McCluskie, Matthew C. Catley, Elizabeth Hardaker, Saleem Haj‐Yahia, Maria G. Belvisi	19
17	Steroid-resistant Inflammation in a Rat Model of Chronic Obstructive Pulmonary Disease Is Associated with a Lack of Nuclear Factor-κB Pathway Activation 2005 ·American Journal of Respiratory and Critical Care Medicine ·Mark A. Birrell, Sissie Wong, David J Hele, Kerryn McCluskie, Elizabeth Hardaker, Maria G. Belvisi	46
18	Iκ-B Kinase-2 Inhibitor Blocks Inflammation in Human Airway Smooth Muscle and a Rat Model of Asthma 2005 ·American Journal of Respiratory and Critical Care Medicine ·Mark A. Birrell, Elizabeth Hardaker, Sissie Wong, Kerryn McCluskie, Matthew C. Catley, Jorge De Alba, Robert Newton, Saleem Haj‐Yahia, Kwok‐Tao Pun, Clarissa J. Watts, (unknown), Tony J. Savage, Maria G. Belvisi	107
19	Prostanoid receptor expression by human airway smooth muscle cells and regulation of the secretion of granulocyte colony-stimulating factor 2005 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Deborah Clarke, Maria G. Belvisi, Susan J. Smith, Elizabeth Hardaker, Magdi H. Yacoub, Koremu Meja, Robert Newton, Donna M. Slater, Mark A. Giembycz	42
20	E-Ring 8-Isoprostanes Are Agonists at EP2- and EP4-Prostanoid Receptors on Human Airway Smooth Muscle Cells and Regulate the Release of Colony-Stimulating Factors by Activating cAMP-Dependent Protein Kinase 2004 ·Molecular Pharmacology ·Deborah Clarke, Maria G. Belvisi, Elizabeth Hardaker, Robert Newton, Mark A. Giembycz	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact